Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

References

• WHO. Ten threats to global health in 2019 [Internet]. [accessed 2019 Apr 3]. https://www.who.int/emergencies/ten-threats-to-global-health-in-2019
   Google Scholar
• Oh M, Park WB, Park S-W, Choe PG, Bang JH, Song K-H, Kim ES, Bin KH, Kim NJ. Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea. Korean J Intern Med. 2018;33:233–46. doi:10.3904/kjim.2018.031.
   PubMed Web of Science ®Google Scholar
• WHO. WHO Director-General summarizes the outcome of the emergency committee regarding clusters of microcephaly and Guillain-Barré syndrome [Internet]. [accessed 2019 Apr 3]. https://www.who.int/en/news-room/detail/01-02-2016-who-director-general-summarizes-the-outcome-of-the-emergency-committee-regarding-clusters-of-microcephaly-and-guillain-barré-syndrome
   Google Scholar
• WHO. WHO publishes list of top emerging diseases likely to cause major epidemics [Internet]. 2015 [accessed 2019 Mar 24]. https://www.who.int/medicines/ebola-treatment/WHO-list-of-top-emerging-diseases/en/
   Google Scholar
• WHO. Methodology for prioritizing severe emerging diseases for research and development background [Internet]. 2017 [accessed 2019 Jun 27]. http://www.who.int/csr/research-and-development/meeting-report-prioritization.pdf?ua=1
   Google Scholar
• WHO. WHO research and development blueprint 2018 annual review of diseases prioritized under the research and development blueprint informal consultation [internet]. [accessed 2019 Jun 28]. http://www.who.int/csr/research-and-development/documents/prioritizing_diseases_progress/en/
   Google Scholar
• Rose J, Schubert M. Rhabdovirus genomes and their Products. In: RR Wagner, editor. The rhabdoviruses. Boston (MA): Springer US; 1987. p. 129–66.
   Google Scholar
• Zemp F, Rajwani J, Mahoney DJ. Rhabdoviruses as vaccine platforms for infectious disease and cancer. Biotechnol Genet Eng Rev. 2018;34:122–38. doi:10.1080/02648725.2018.1474320.
   PubMed Web of Science ®Google Scholar
• Lawson ND, Stillmans EA, Whitt MA, Rose JK. Recombinant vesicular stomatitis viruses from DNA. PNAS. 1995;92:4477–81. doi:10.1073/pnas.92.10.4477.
   PubMed Web of Science ®Google Scholar
• Roberts A, Buonocore L, Price R, Forman J, Rose JK, Roberts A, Kretzschmar E, Perkins AS, Forman J, Price R, et al. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol. 1999;73:3723–32.
   PubMed Web of Science ®Google Scholar
• Clarke DK, Nasar F, Lee M, Johnson JE, Wright K, Calderon P, Guo M, Natuk R, Cooper D, Hendry RM, et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G Gene truncations and N Gene translocations. J Virol. 2007;81:2056. doi:10.1128/JVI.01911-06.
   PubMed Web of Science ®Google Scholar
• Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D, Roberts A, Buonocore L, Rose JK. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 2001;106:539–49. doi:10.1016/S0092-8674(01)00482-2.
   PubMed Web of Science ®Google Scholar
• Mcgettigan JP, Sarma S, Orenstein JM, Pomerantz RJ, Schnell MJ. Expression and immunogenicity of human immunodeficiency virus type 1 gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol. 2001;75:8724–32. doi:10.1128/JVI.75.18.8724-8732.2001.
   PubMed Web of Science ®Google Scholar
• Clarke DK, Michael Hendry R, Singh V, Rose JK, Seligman SJ, Klug B, Kochhar S, Mac LM, Carbery B, Chen RT. Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine. 2016;34:6597–609. doi:10.1016/j.vaccine.2016.10.045.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and marburg virus infections. J Infect Dis. 2011;204:S1075–1081. doi:10.1093/infdis/jir349.
   PubMed Web of Science ®Google Scholar
• Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, Nichols R, Heppner DG, Simon JK, Dubey S, et al. rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: standardized template with key considerations for a risk/benefit assessment. Vaccine X. 2019;1:100009. doi:10.1016/j.jvacx.2019.100009.
   PubMedGoogle Scholar
• Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Möller P, Wagner R, Volchkov V, Klenk H-D, Feldmann H, Ströher U. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004;78:5458–65. doi:10.1128/JVI.78.10.5458-5465.2004.
   PubMed Web of Science ®Google Scholar
• Rose NF, Roberts A, Buonocore L, Rose JK. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol. 2000;74:10903–10. doi:10.1128/JVI.74.23.10903-10910.2000.
   PubMed Web of Science ®Google Scholar
• Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams SA, Tomaras GD, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090). Open Forum Infect Dis. 2015;2:ofv082. doi:10.1093/ofid/ofv082.
   PubMed Web of Science ®Google Scholar
• Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol. 2010;155:2083–103. doi:10.1007/s00705-010-0677-1.
   PubMed Web of Science ®Google Scholar
• Goldstein T, Anthony SJ, Gbakima A, Bird BH, Bangura J, Tremeau-Bravard A, Belaganahalli MN, Wells HL, Dhanota JK, Liang E, et al. The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nat Microbiol. 2018;3:1084–89. doi:10.1038/s41564-018-0227-2.
   PubMed Web of Science ®Google Scholar
• WHO. WHO | statement on the 1st meeting of the IHR emergency committee on the 2014 Ebola outbreak in West Africa [Internet]. WHO2014. [accesed 2019 Mar 6]. https://www.who.int/mediacentre/news/statements/2014/ebola-20140808/en/
   Google Scholar
• Plummer FA, Jones SM. The story of Canada’s Ebola vaccine. CMAJ. 2017;189:E1326–7. doi:10.1503/cmaj.170704.
   PubMed Web of Science ®Google Scholar
• Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, Klenk H-D, Sullivan NJ, Volchkov VE, Fritz EA, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11:786–90. doi:10.1038/nm1258.
   PubMed Web of Science ®Google Scholar
• Qiu X, Fernando L, Alimonti JB, Leno Melito P, Feldmann F, Dick D, Ströher U, Feldmann H, Jones SM. Mucosal immunization of cynomolgus macaques with the VSVDG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One. 2009;4:e5547. doi:10.1371/journal.pone.0005547.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, Ströher U, Fritz EA, Hensley LE, Jones SM, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2012;26:6894–900. doi:10.1016/j.vaccine.2008.09.082.
   Web of Science ®Google Scholar
• Jones SM, Ströher U, Fernando L, Qiu X, Alimonti J, Melito P, Bray M, Klenk H-D, Feldmann H, Strö U, et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis. 2007;196:404–12. doi:10.1086/520591.
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer J-A, Kraehling V, Kasonta R, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med. 2016;374:1647–60. doi:10.1056/NEJMoa1502924.
   PubMed Web of Science ®Google Scholar
• Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, et al. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med. 2017;376:330–41. doi:10.1056/NEJMoa1414216.
   PubMed Web of Science ®Google Scholar
• ElSherif MS, Brown C, Mackinnon-Cameron D, Li L, Racine T, Alimonti J, Rudge TL, Sabourin C, Silvera P, Hooper JW, et al. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: A randomized clinical trial. CMAJ. 2017;189:819–27. doi:10.1503/cmaj.171389.
   PubMed Web of Science ®Google Scholar
• Heppner DG, Kemp TL, Martin BK, Ramsey WJ, Nichols R, Dasen EJ, Link CJ, Das R, Xu ZJ, Sheldon EA, et al. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017;17:854–66. doi:10.1016/S1473-3099(17)30242-6.
   PubMed Web of Science ®Google Scholar
• Coller B-AG, Blue J, Das R, Dubey S, Finelli L, Gupta S, Helmond F, Grant-Klein RJ, Liu K, Simon J, et al. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 2017;35:4465–69. doi:10.1016/j.vaccine.2017.05.097.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds J, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389:505–18. doi:10.1016/S0140-6736(16)32621-6.
   PubMed Web of Science ®Google Scholar
• Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, Eckes R, Feinberg M, Follmann D, Grund B, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. 2017;377:1438–47. doi:10.1056/NEJMoa1614067.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Arribas JR, Rupp R, Andrews CP, Chu L, Das R, Simon JK, Onorato MT, Liu K, Martin J, et al. Six-month safety data of recombinant vesicular stomatitis virus–zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis. 2017;215:1789–98. doi:10.1093/infdis/jix189.
   PubMed Web of Science ®Google Scholar
• Juan-Giner A, Tchaton M, Jemmy J-P, Soumah A, Boum Y, Faga EM, Cisse M, Grais RF. Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea. Vaccine. 2018;S0264-410X:31246–5.
   Google Scholar
• Samai M, Seward JF, Goldstein ST, Mahon BE, Lisk DR, Widdowson M-A, Jalloh MI, Schrag SJ, Idriss A, Carter RJ, et al. The sierra leone trial to introduce a vaccine against Ebola: an evaluation of rVSV∆G-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak. J Infect Dis. 2018;6:217.
   Google Scholar
• WHO. Strategic Advisory Group of Experts (SAGE) on immunization interim recommendations on vaccination against Ebola Virus Disease (EVD) [internet]. 2019 [accessed 2019 Jun 28]. www.who.int/immunization/sage/meetings/2019/april/SAGE_April_2019_meeting_summary.pdf?ua=1,
   Google Scholar
• Huttner A, Dayer J-A, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15:1156–66. doi:10.1016/S1473-3099(15)00154-1.
   PubMed Web of Science ®Google Scholar
• Huttner A, Agnandji ST, Combescure C, Fernandes JF, Bache EB, Kabwende L, Ndungu FM, Brosnahan J, Monath TP, Lemaître B, et al. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2018;18:738–48. doi:10.1016/S1473-3099(18)30165-8.
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Fernandes JF, Bache EB, Mba RMO, Brosnahan JS, Kabwende L, Pitzinger P, Staarink P, Massinga-Loembe M, Krähling V, et al. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial. PLoS Med. 2017;14:e1002402. doi:10.1371/journal.pmed.1002230.
   PubMed Web of Science ®Google Scholar
• Kasereka MC, Sawatzky J, Hawkes MT. Ebola epidemic in war-torn democratic republic of congo, 2018: acceptability and patient satisfaction of the recombinant vesicular stomatitis virus - Zaire Ebolavirus vaccine. Vaccine. 2019;37:2174–78. doi:10.1016/j.vaccine.2019.03.004.
   PubMed Web of Science ®Google Scholar
• Gsell P-S, Camacho A, Kucharski AJ, Watson CH, Bagayoko A, Nadlaou SD, Dean NE, Diallo A, Diallo A, Honora DA, et al. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. Lancet Infect Dis. 2017;17:1276–84. doi:10.1016/S1473-3099(17)30242-6.
   PubMed Web of Science ®Google Scholar
• The PREVENT Working Group. Pregnant women & vaccines against emerging epidemic threats [Internet]. Prev Work Gr. [accessed 2019 Mar 17]. https://www.who.int/immunization/sage/meetings/2018/october/1_PREVENT_Recs_Excerpts_for_SAGE.PDF.
   Google Scholar
• Caluwaerts S. Nubia’s mother: being pregnant in the time of experimental vaccines and therapeutics for Ebola. Reprod Health. 2017;14:157. doi:10.1186/s12978-017-0429-8.
   PubMed Web of Science ®Google Scholar
• Branswell H. Ebola vaccine will be given to pregnant women, marking reversal in policy [internet]. [accssed 2019 Mar 23]. https://www.statnews.com/2019/02/20/ebola-pregnancy-reversal/
   Google Scholar
• RDC. EBOLA RDC - Evolution de la riposte contre l’épidémie d’Ebola dans les provinces du Nord Kivu et de l’Ituri au Samedi 15 juin 2019 [Internet]. 2019 [accessed 2019 Jun 28]. https://mailchi.mp/sante.gouv.cd/ebola_kivu_15juin19?e=77c16511ad
   Google Scholar
• Jones SM, Ströher U, Fernando L, Qiu X, Alimonti J, Melito P, Bray M, Klenk H-D, Feldmann H. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis. 2007;196:S404–412. doi:10.1086/520591.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A. vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008;4:1000225. doi:10.1371/journal.ppat.1000225.
   PubMed Web of Science ®Google Scholar
• Marzi A, Robertson SJ, Haddock E, Feldmann F, Hanley PW, Scott DP, Strong JE, Kobinger G, Best SM, Feldmann H. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science. 2015;349:739–42. doi:10.1126/science.aab3920.
   PubMed Web of Science ®Google Scholar
• Maria Henao-Restrepo A, Longini IM, Egger M, Dean NE, John Edmunds W, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraff Our S, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386:857–66. doi:10.1016/S0140-6736(15)61137-0.
   PubMed Web of Science ®Google Scholar
• Metzger WG, Vivas-Martínez S. Questionable efficacy of the rVSV-ZEBOV Ebola vaccine. Lancet. 2018;391:1021. doi:10.1016/S0140-6736(18)30302-7.
   PubMed Web of Science ®Google Scholar
• Longini IM, Røttingen J-A, Kieny MP, Edmunds WJ, Henao-Restrepo AM. Questionable efficacy of the rVSV-ZEBOV Ebola vaccine – authors’ reply. Lancet. 2018;391:1021–22. doi:10.1016/S0140-6736(18)30302-7.
   PubMed Web of Science ®Google Scholar
• Merck. Merck begins rolling submission of licensure application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and drug administration [internet]. 2018 [accessed 2019 Mar 16]. https://investors.merck.com/news/press-release-details/2018/Merck-Begins-Rolling-Submission-of-Licensure-Application-for-V920-rVSVG-ZEBOV-GP-to-US-Food-and-Drug-Administration/default.aspx
   Google Scholar
• Marzi A, Mire CE. Current Ebola virus vaccine progress. BioDrugs. 2019;33:9–14. doi:10.1007/s40259-018-0329-7.
   PubMed Web of Science ®Google Scholar
• Haug CJ. Keeping your cool — doing Ebola research during an emergency. NEJM. 2018;378:2353–55. doi:10.1056/NEJMc1711583.
   PubMed Web of Science ®Google Scholar
• Gsell P-S, Camacho A, Kucharski AJ, Watson CH, Bagayoko A, Danmadji Nadlaou S, Dean NE, Diallo A, Diallo A, Honora DA, et al. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. Lancet Infect Dis. 2017;17:1276–84. doi:10.1016/S1473-3099(17)30242-6.
   PubMed Web of Science ®Google Scholar
• WHO. Ebola Virus Disease Democratic Republic of the Congo External Situation Report 17 [Internet]. 2018 [accessed 2019 Apr 9]. http://www.who.int/ebola/historical-outbreaks-drc/en/.
   Google Scholar
• Ministère de la Santé RD du C. EBOLA RDC - Evolution de la riposte contre l’épidémie d’Ebola dans les provinces du Nord Kivu et de l’Ituri au Lundi 22 juillet 2019 [Internet]. 2019 [accessed 2019 Jul 30]. https://us13.campaign-archive.com/?u=89e5755d2cca4840b1af93176&id=1af4c6a868
   Google Scholar
• WHO. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. [Internet]. 2019 [accessed 2019 Jun 14]. https://www.who.int/csr/resources/publications/ebola/ebola-ring-vaccination-results-12-april-2019.pdf
   Google Scholar
• Widdowson M-A, Schrag SJ, Carter RJ, Carr W, Legardy-Williams J, Gibson L, Lisk DR, Jalloh MI, Bash-Taqi DA, Kargbo SAS, et al. Implementing an Ebola vaccine study-sierra leone background to trial conception. MMWR. 2016;65:98–106. doi:10.15585/mmwr.su6503a14.
   PubMed Web of Science ®Google Scholar
• Arnemo M, Sofie S, Watle V, Merete Schoultz K, Vainio K, Norheim G, Moorthy V, Fast P, Røttingen J-A, Gjøen T. Stability of a vesicular stomatitis virus-vectored Ebola vaccine. J Infect Dis. 2016;213:930–33. doi:10.1093/infdis/jiv532.
   PubMed Web of Science ®Google Scholar
• Stein DR, Sroga P, Warner BM, Deschambault Y, Poliquin G, Safronetz D. Evaluating temperature sensitivity of vesicular stomatitis virus–based vaccines. Emerg Infect Dis. 2019 [accessed 2019 Jul 26];25:1563–66. http://wwwnc.cdc.gov/eid/article/25/8/19-0281_article.htm.
   PubMed Web of Science ®Google Scholar
• Ruibal P, Oestereich L, Lüdtke A, Becker-Ziaja B, Wozniak DM, Kerber R, Korva M, Cabeza-Cabrerizo M, Bore JA, Koundouno FR, et al. Unique human immune signature of Ebola virus disease in Guinea. Nature. 2016;533:100–04. doi:10.1038/nature17949.
   PubMed Web of Science ®Google Scholar
• Liu X, Speranza E, Muñoz-Fontela C, Haldenby S, Rickett NY, Garcia-Dorival I, Fang Y, Hall Y, Zekeng E-G, Lüdtke A, et al. Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. Genome Biol. 2017;18:4. doi:10.1186/s13059-016-1137-3.
   PubMed Web of Science ®Google Scholar
• Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. PNAS. 2013;110:1893–98. doi:10.1073/pnas.1209591110.
   PubMed Web of Science ®Google Scholar
• Menicucci AR, Jankeel A, Feldmann H, Marzi A, Messaoudi I. Antiviral innate responses induced by VSV-EBOV vaccination contribute to rapid protection. MBio. 2019;10. doi:10.1128/mBio.00669-19.
   PubMed Web of Science ®Google Scholar
• Gross L, Lhomme E, Pasin C, Richert L, Thiebaut R. Ebola vaccine development: systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. Int J Infect Dis. 2018;74:83–96. doi:10.1016/j.ijid.2018.06.022.
   PubMed Web of Science ®Google Scholar
• Farooq F, Beck K, Paolino KM, Phillips R, Waters NC, Regules JA, Bergmann-Leitner ES. Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine. Sci Rep. 2016;6:1–9. doi:10.1038/srep27944.
   PubMed Web of Science ®Google Scholar
• Dahlke C, Kasonta R, Lunemann S, Krähling V, Zinser ME, Biedenkopf N, Fehling SK, Ly ML, Rechtien A, Stubbe HC, et al. Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization. EBioMedicine. 2017;19:107–18. doi:10.1016/j.ebiom.2017.03.045.
   PubMed Web of Science ®Google Scholar
• Rechtien A, Richert L, Lorenzo H, Martrus G, Hejblum B, Dahlke C, Kasonta R, Zinser M, Stubbe H, Matschl U, et al. Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV. Cell Rep. 2017;20:2251–61. doi:10.1016/j.celrep.2017.08.023.
   PubMed Web of Science ®Google Scholar
• Huttner A, Combescure C, Grillet S, Haks MC, Quinten E, Modoux C, Todagbe Agnandji S, Brosnahan J, Dayer J-A, Harandi AM, et al. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. Sci Transl Med. 2017;9. doi:10.1126/scitranslmed.aaj1701.
   PubMed Web of Science ®Google Scholar
• Feldmann H, Jones SM, Daddario-Dicaprio KM, Geisbert JB, Strö Her U, Grolla A, Bray M, Fritz EA, Fernando L, Feldmann F, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007;3:e2. doi:10.1371/journal.ppat.0030002.
   PubMed Web of Science ®Google Scholar
• Marzi A, Hanley PW, Haddock E, Martellaro C, Kobinger G, Feldmann H. Efficacy of vesicular stomatitis virus-Ebola virus postexposure treatment in rhesus macaques infected with Ebola virus makona. J Infect Dis. 2016;214:S360–6. doi:10.1093/infdis/jiw389.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Williams KJN, Geisbert JB, Leung A, Feldmann F, Hensley LE, Feldmann H, Jones SM. Recombinant vesicular stomatitis virus vector mediates postexposure protection against sudan Ebola hemorrhagic fever in nonhuman primates. J Virol. 2008;82:5664–68. doi:10.1128/JVI.01931-07.
   PubMed Web of Science ®Google Scholar
• Fischer WA, Vetter P, Bausch DG, Burgess T, Davey RT, Fowler R, Hayden FG, Jahrling PB, Kalil AC, Mayers DL, et al. Ebola virus disease: an update on post-exposure prophylaxis. Rev Lancet Infect Dis. 2018;18:e183–92. doi:10.1016/S1473-3099(17)30677-1.
   PubMed Web of Science ®Google Scholar
• Günther S, Feldmann H, Geisbert TW, Hensley LE, Rollin PE, Nichol ST, Ströher U, Artsob H, Peters CJ, Ksiazek TG, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis. 2011;204(Suppl):S785–90. doi:10.1093/infdis/jir298.
   PubMed Web of Science ®Google Scholar
• Lai L, Davey R, Beck A, Xu Y, Suffredini AF, Palmore T, Kabbani S, Rogers S, Kobinger G, Alimonti J, et al. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA. 2015;313:1249–55. doi:10.1001/jama.2015.1995.
   PubMed Web of Science ®Google Scholar
• Wong KK, Davey RT, Hewlett AL, Kraft CS, Mehta AK, Mulligan MJ, Beck A, Dorman W, Kratochvil CJ, Lai L, et al. Use of postexposure prophylaxis after occupational exposure to Zaire ebolavirus. Clin Infect Dis. 2016;63:376–79. doi:10.1093/cid/ciw256.
   PubMed Web of Science ®Google Scholar
• Poetsch JH, Dahlke C, Zinser ME, Kasonta R, Lunemann S, Rechtien A, Ly ML, Stubbe HC, Krähling V, Biedenkopf N, et al. Detectable Vesicular Stomatitis Virus (VSV)–specific humoral and cellular immune responses following VSV–Ebola virus vaccination in humans. J Infect Dis. 2018;219:556–61. doi:10.1093/infdis/jiy565.
   Web of Science ®Google Scholar
• Marzi A, Feldmann F, Geisbert TW, Feldmann H, Safronetz D. Vesicular stomatitis virus–based vaccines against lassa and Ebola viruses. Emerg Infect Dis. 2015;21:305–07. doi:10.3201/eid2101.140256.
   PubMed Web of Science ®Google Scholar
• Locher S, Schweneker M, Hausmann J, Zimmer G. Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs. J Gen Virol. 2018;99:866–79. doi:10.1099/jgv.0.001031.
   PubMed Web of Science ®Google Scholar
• Matassov D, Marzi A, Latham T, Xu R, Ota-Setlik A, Feldmann F, Geisbert JB, Mire CE, Hamm S, Nowak B, et al. Vaccination with a highly attenuated recombinant vesicular stomatitis virus vector protects against challenge with a lethal dose of Ebola virus. J Infect Dis. 2015;212:443–51. doi:10.1093/infdis/jiv316.
   Web of Science ®Google Scholar
• Elizaga IDML, Li SS, Kochar NK, Wilson GJ, Allen IDMA, Van Tieu HN, Frank I, Sobieszczyk ME, Cohen KW, Sanchez B, et al. Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial. PLoS One. 2018;13:e0202753. doi:10.1371/journal.pone.0202753.
   PubMed Web of Science ®Google Scholar
• Mire CE, Matassov D, Geisbert JB, Latham TE, Agans KN, Xu R, Ota-Setlik A, Egan MA, Fenton KA, Clarke DK, et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature. 2015;520:688–94. doi:10.1038/nature14428.
   PubMed Web of Science ®Google Scholar
• WHO | Marburg virus disease. WHO [Internet] 2017 [accessed 2019 Apr 9]. http://origin.who.int/mediacentre/factsheets/fs_marburg/en/
   Google Scholar
• Reynolds P, Ebola MA. Marburg virus vaccines. Virus Genes. 2017;53:501–15. doi:10.1007/s11262-017-1455-x.
   PubMed Web of Science ®Google Scholar
• Cross RW, Mire CE, Feldmann H, Geisbert TW. Post-exposure treatments for Ebola and Marburg virus infections. Nat Rev Drug Discov. 2018;17:413–34. doi:10.1038/nrd.2017.251.
   PubMed Web of Science ®Google Scholar
• Daddario-Dicaprio KM, Geisbert TW, Geisbert JB, Ströher U, Hensley LE, Grolla A, Fritz EA, Feldmann F, Feldmann H, Jones SM. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol. 2006;80:9659–66. doi:10.1128/JVI.00959-06.
   PubMed Web of Science ®Google Scholar
• Daddario-Dicaprio KM, Geisbert TW, Ströher U, Geisbert JB, Grolla A, Fritz EA, Fernando L, Kagan E, Jahrling PB, Hensley LE, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet. 2006;367:1399–404. doi:10.1016/S0140-6736(06)68546-2.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Geisbert JB, Leung A, Johnson JC, Grolla A, Feldmann H. Postexposure treatment of Marburg virus infection. Emerg Infect Dis. 2010;16:1119–22.
   PubMed Web of Science ®Google Scholar
• Woolsey C, Geisbert JB, Matassov D, Agans KN, Borisevich V, Cross RW, Deer DJ, Fenton KA, Eldridge JH, Mire CE, et al. Postexposure efficacy of recombinant vesicular stomatitis virus vectors against high and low doses of marburg virus variant angola in nonhuman primates. J Infect Dis. 2018;218:582–87. doi:10.1093/infdis/jiy293.
   PubMed Web of Science ®Google Scholar
• Mire CE, Geisbert JB, Agans KN, Satterfield BA, Versteeg KM. Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates. PLoS One. 2014;9:e94355. doi:10.1371/journal.pone.0094355.
   PubMed Web of Science ®Google Scholar
• Nachbagauer R, Connor J, Marzi A, Menicucci AR, Engelmann F, Callison J, Horne EJ, Feldmann F, Jankeel A, Feldmann H, et al. Protection against marburg virus using a recombinant VSV-vaccine depends on T and B cell activation. Front Immunol. 2019;9. doi:10.3389/fimmu.2018.03122.
   Web of Science ®Google Scholar
• Falzarano D, Feldmann F, Grolla A, Leung A, Ebihara H, Strong JE, Marzi A, Takada A, Jones S, Gren J, et al. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with bundibugyo ebolavirus. J Infect Dis. 2011;204:S1082–S1089. doi:10.1093/infdis/jir350.
   PubMed Web of Science ®Google Scholar
• Mire CE, Geisbert JB, Marzi A, Agans KN, Feldmann H, Geisbert TW. Vesicular stomatitis virus-based vaccines protect nonhuman primates against bundibugyo ebolavirus. PLoS Negl Trop Dis. 2013;7:e2600. doi:10.1371/journal.pntd.0002600.
   PubMed Web of Science ®Google Scholar
• TW G, JB G, Leung A, KM D-D, LE H, Grolla A, Feldmann H. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of Ebola virus. J Virol. 2009;83:7296–304. doi:10.1128/JVI.02516-08.
   PubMed Web of Science ®Google Scholar
• Matassov D, Mire CE, Latham T, Geisbert JB, Xu R, Ota-Setlik A, Agans KN, Kobs DJ, Wendling MQS, Burnaugh A, et al. Single-dose trivalent vesiculovax vaccine protects macaques from lethal ebolavirus and marburgvirus challenge. J Virol. 2018;92:e01190–17. doi:10.1128/JVI.01190-17.
   PubMed Web of Science ®Google Scholar
• Profectus Biosciences. Profectus biosciences awarded NIH contract for up to $22.25 million to develop multi-component vaccine for Ebola, Marburg, and Lassa viruses [Internet]. 2017 [accessed 2019 Mar 5]. www.profectusbiosciences.com
   Google Scholar
• Warner BM, Safronetz D, Stein DR. Current research for a vaccine against Lassa hemorrhagic fever virus. Drug Des Devel Ther. 2018;12:2519–27. doi:10.2147/DDDT.S147276.
   PubMed Web of Science ®Google Scholar
• Nigeria Center for Disease Control (NCDC). 2019 LASSA Fever Outbreak Situation report week 13 [Internet]. [accessed 2019 Apr 9]. https://ncdc.gov.ng/diseases/sitreps/?cat=5&name=An update of Lassa fever outbreak in Nigeria
   Google Scholar
• Plotkin SA. Vaccines for epidemic infections and the role of CEPI. Hum Vaccin Immunother. 2017;13:2755–62. doi:10.1080/21645515.2017.1306615.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, Grolla A, Strö Her U, Fernando L, Daddario KM, et al. Development of a New Vaccine for the Prevention of Lassa Fever. PLoS Med. 2005;2:e183. doi:10.1371/journal.pmed.0020183.
   PubMed Web of Science ®Google Scholar
• Safronetz D, Mire C, Rosenke K, Feldmann F, Haddock E, Geisbert T, Feldmann H. A recombinant vesicular stomatitis virus-based lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl Trop Dis. 2015;9:e0003736. doi:10.1371/journal.pntd.0003736.
   PubMed Web of Science ®Google Scholar
• Kafetzopoulou LE, Pullan ST, Lemey P, Suchard MA, Ehichioya DU, Pahlmann M, Thielebein A, Hinzmann J, Oestereich L, Wozniak DM, et al. Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. Science. 2019;363:74–77. doi:10.1126/science.aau9343.
   PubMed Web of Science ®Google Scholar
• Stein DR, Warner BM, Soule G, Tierney K, Frost KL, Booth S, Safronetz D. A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. NPJ Vaccines. 2019;4. doi:10.1038/s41541-019-0104-x.
   PubMed Web of Science ®Google Scholar
• Profectus Biosciences. CEPI awards contract worth up to $36 million to profectus biosciences and emergent biosolutions to develop lassa virus vaccine [Internet]. 2018 [accessed 2019 Mar 5]. http://www.profectusbiosciences.com/news/releases.html
   Google Scholar
• Rodriguez SE, Cross RW, Fenton KA, Bente DA, Mire CE, Geisbert TW. Vesicular stomatitis virus-based vaccine protects mice against crimean-congo hemorrhagic fever. Sci Rep. 2019;9. doi:10.1038/s41598-019-44210-6.
   Web of Science ®Google Scholar
• Chattopadhyay A, Rose JK. Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach. J Virol. 2011;85:2004–11. doi:10.1128/JVI.01852-10.
   PubMed Web of Science ®Google Scholar
• Van Den Pol AN, Mao G, Chattopadhyay A, Rose JK, Davis JN. Chikungunya, influenza, Nipah, and semliki forest chimeric viruses with vesicular stomatitis virus: actions in the brain. J Virol. 2017;91:e02154–16. doi:10.1128/JVI.02154-16.
   PubMed Web of Science ®Google Scholar
• Lo MK, Bird BH, Chattopadhyay A, Drew CP, Martin BE, Coleman JD, Rose JK, Nichol ST, Spiropoulou CF. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Res. 2014;101:26–29. doi:10.1016/j.antiviral.2013.10.012.
   PubMed Web of Science ®Google Scholar
• Debuysscher BL, Scott D, Marzi A, Prescott J, Feldmann H. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine. 2014;32:2637–44. doi:10.1016/j.vaccine.2014.02.087.
   PubMed Web of Science ®Google Scholar
• Debuysscher BL, Scott D, Thomas T, Feldmann H, Prescott J. Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine. NPJ Vaccines. 2016;1:16002. doi:10.1038/npjvaccines.2016.2.
   PubMed Web of Science ®Google Scholar
• Prescott J, Debuysscher BL, Feldmann F, Gardner DJ, Haddock E, Martellaro C, Scott D, Feldmann H. Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah Virus disease. Vaccine. 2015;33:2823–29. doi:10.1016/j.vaccine.2015.03.089.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Hickey AC, Smith MA, Chan Y-P. Development of an acute and highly pathogenic nonhuman primate model of nipah virus infection. PLoS One. 2010;5:10690. doi:10.1371/journal.pone.0010690.
   PubMed Web of Science ®Google Scholar
• Kapadia SU, Simon ID, Rose JK. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. Virology. 2008;376:165–72. doi:10.1016/j.virol.2008.03.002.
   PubMed Web of Science ®Google Scholar
• Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology. 2005;340:174–82. doi:10.1016/j.virol.2005.06.007.
   PubMed Web of Science ®Google Scholar
• Liu R, Wang J, Shao Y, Wang X, Zhang H, Shuai L, Ge J, Wen Z, Bu Z. A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization. Antiviral Res. 2018;150:30–38. doi:10.1016/j.antiviral.2017.12.007.
   PubMed Web of Science ®Google Scholar
• Modjarrad K, Moorthy VS, Ben Embarek P, Van Kerkhove M, Kim J, Kieny M-P A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation. Nat Med 2016; 22:701–05. doi:10.1038/nm.4131
   PubMed Web of Science ®Google Scholar
• Zanluca C, Campos Andrade de Melo V, Luiza Pamplona Mosimann A, Igor Viana Dos Santos G, Nunes Duarte Dos Santos C, Luz K. First report of autochthonous transmission of Zika virus in Brazil. Mem Inst Oswaldo Cruz Rio Janeiro 2015; 110:569–72. doi:10.1590/0074-02760150192
   PubMed Web of Science ®Google Scholar
• Gatherer D, Kohl A. Zika virus: a previously slow pandemic spreads rapidly through the Americas. J Gen Virol. 2016;97:269–73. doi:10.1099/jgv.0.000381.
   PubMed Web of Science ®Google Scholar
• Betancourt D, De Queiroz NMGP, Xia T, Ahn J, Barber GN. cutting Edge: innate immune augmenting vesicular stomatitis virus expressing zika virus proteins confers protective immunity. J Immunol. 2017;198:3023–28. doi:10.4049/jimmunol.1602180.
   PubMed Web of Science ®Google Scholar
• Emanuel J, Callison J, Dowd KA, Pierson TC, Feldmann H, Marzi A. A VSV-based Zika virus vaccine protects mice from lethal challenge. Sci Rep. 2018;8:11043. doi:10.1038/s41598-018-29401-x.
   PubMed Web of Science ®Google Scholar
• Li A, Yu J, Lu M, Ma Y, Attia Z, Shan C, Xue M, Liang X, Craig K, Makadiya N, et al. A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat Commun. 2018;9:1–17.
   PubMed Web of Science ®Google Scholar
• Shi X, Hu J, Guo J, Wu C, Xiong S, Dong C. A vesicular stomatitis virus-based vaccine carrying zika virus capsid protein protects mice from viral infection. Virol Sin. 2019;34:106–10. doi:10.1007/s12250-019-00083-7.
   PubMed Web of Science ®Google Scholar
• Yan Q, Wu L, Chen L, Qin Y, Pan Z, Chen M. Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges. Vaccine. 2016;34:4196–204. doi:10.1016/j.vaccine.2016.10.045.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay A, Wang E, Seymour R, Weaver SC, Rose JK. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. J Virol. 2013;87:395–402. doi:10.1128/JVI.01860-12.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay A, Aguilar PV, Bopp NE, Yarovinsky TO, Weaver SC, Rose JK. A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections. Vaccine. 2018;36:3894–900. doi:10.1016/j.vaccine.2018.05.095.
   PubMed Web of Science ®Google Scholar
• Iyer AV, Pahar B, Boudreaux MJ, Wakamatsu N, Roy AF, Chouljenko VN, Baghian A, Apetrei C, Marx PA, Kousoulas KG. Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01. Vaccine. 2009;27:893–903. doi:10.1016/j.vaccine.2008.11.087.
   PubMed Web of Science ®Google Scholar
• Lauretti F, Chattopadhyay A, Freitas De Oliveira França R, Castro-Jorge L, Rose J, Da Fonseca BAL. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection. Hum Vaccin Immunother. 2016;12:2327–33. doi:10.1080/21645515.2016.1208328.
   PubMed Web of Science ®Google Scholar
• Dong F, Li D, Wen D, Li S, Zhao C, Qi Y, Jangra RK, Wu C, Xia D, Zhang X, et al. Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus. NPJ Vaccines. 2019 Jan 25;4:5. eCollection 2019. doi:10.1038/s41541-018-0096-y.
   Web of Science ®Google Scholar
• Prescott J, Debuysscher BL, Brown KS, Feldmann H. Long-term single-dose efficacy of a vesicular stomatitis virus-based andes virus Vaccine in syrian hamsters. Viruses. 2014;6:516–23. doi:10.3390/v6020516.
   PubMed Web of Science ®Google Scholar
• Tsuda Y, Safronetz D, Brown K, Lacasse R, Marzi A, Ebihara H, Feldmann H. Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the syrian hamster model of lethal ebola virus infection. J Infect Dis. 2011;204:S1090–1097. doi:10.1093/infdis/jir379.
   PubMed Web of Science ®Google Scholar
• Brown KS, Safronetz D, Marzi A, Ebihara H, Feldmann H. Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J Virol. 2011;85:12781–91. doi:10.1128/JVI.00794-11.
   PubMed Web of Science ®Google Scholar